Targeting the untargetable: Recent advances in the selective chemical modulation of protein phosphatase-1 activity

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 361-368

  Chatterjee, Jayanta ^a   Köhn, Maja ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALYCULIN A; CANTHARIDIN; GUANABENZ; MICROCYSTIN LR; NODULARIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; REGULATOR PROTEIN; SALUBRINAL; TAUTOMYCIN;

BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HYPERTENSION; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME INHIBITORS; PROTEIN PHOSPHATASE 1;

EID: 84878878492     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.008     Document Type: Review

References (49)

1. Brautigan D.L. Protein Ser/Thr phosphatases-the ugly ducklings of cell signalling. FEBS J 2013, 280:324-345.
2. McConnell J.L., Wadzinski B.E. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 2009, 75:1249-1261.
3. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
4. Tsaytler P., Bertolotti A. Exploiting the selectivity of protein phosphatase 1 for pharmacological intervention. FEBS J 2013, 280:766-770.
5. + cancers. Cancer Res 2010, 70:5438-5447.
6. Bollen M., Peti W., Ragusa M.J., Beullens M. The extended PP1 toolkit: designed to create specificity. Trends Biochem Sci 2010, 35:450-458.
7. Heroes E., Lesage B., Görnemann J., Beullens M., Van Meervelt L., Bollen M. The PP1 binding code: a molecular-lego strategy that governs specificity. FEBS J 2013, 280:584-595.
8. Virshup D.M., Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009, 33:537-545.
9. Hendrickx A., Beullens M., Ceulemans H., Den Abt T., Van Eynde A., Nicolaescu E., Lesage B., Bollen M. Docking motif-guided mapping of the interactome of protein phosphatase-1. Chem Biol 2009, 16:365-371.
10. Landsverk H.B., Mora-Bermúdez F., Landsverk O.J.B., Hasvold G., Naderi S., Bakke O., Ellenberg J., Collas P., Syljuåsen R.G., Küntziger T. The protein phosphatase 1 regulator PNUTS is a new component of the DNA damage response. EMBO Rep 2010, 11:868-875.
11. Qian J., Lesage B., Beullens M., Van Eynde A., Bollen M. PP1/Repo-Man dephosphorylates mitotic histone H3 at T3 and regulates chromosomal Aurora B targeting. Curr Biol 2011, 21:766-773.
12. 2+ cycling. Cardiovasc Res 2011, 89:79-88.
13. Cougot D., Allemand E., Riviére L., Benhenda S., Duroure K., Levillayer F., Muchardt C., Buendia M.A., Neuveut C. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci Signal 2012, 5:ra1.
14. Ammosova T., Yedavalli V.R., Niu X., Jerebtsova M., Van Eynde A., Beullens M., Bollen M., Jeang K.T., Nekhai S. Expression of a protein phosphatase-1 inhibitor, cdNIPP1, increases CDK9 threonine 186 phosphorylation and inhibits HIV-1 transcription. J Biol Chem 2011, 286:3798-3804.
15. Kuehnen P., Laubner K., Raile K., Schöfl C., Jakob F., Pilz I., Päth G., Seufert J. Protein phosphatase 1 (PP1)-dependent inhibition of insulin secretion by leptin in INS-1 pancreatic β-cells and human pancreatic islets. Endocrinology 2011, 152:1800-1808.
16. Martin-Granados C., Prescott A.R., Van Dessel N., Van Eynde A., Arocena M., Klaska I.P., Görnemann J., Beullens M., Bollen M., Forrester J.V., et al. A role for PP1/NIPP1 in steering migration of human cancer cells. PLoS ONE 2012, 7:e40769.
17. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., Weiser D., Hahn H., Carr A.N., Syed F., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005, 96:756-766.
18. Fardilha M., Esteves S.L.C., Korrodi-Gregoório L., da Cruz e Silva O.A.B., da Cruz e Silva E.F. The physiological relevance of protein phosphatase 1 and its interacting proteins to health and disease. Curr Med Chem 2010, 17:3996-4017.
19. Cho U.S., Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 2007, 445:53-57.
20. Fagerholm A.E., Habrant D., Koskinen A.M. Calyculins and related marine natural products as serine-threonine protein phosphatase PP1 and PP2A inhibitors and total syntheses of calyculin A, B, and C. Mar Drugs 2010, 8:122-172.
21. Aggen J.B., Humphrey J.M., Gauss C.M., Huang H.B., Nairn A.C., Chamberlin A.R. The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity. Bioorg Med Chem 1999, 7:543-564.
22. Swingle M., Ni L., Honkanen R.E. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 2007, 365:23-38.
23. Kwon Y.G., Huang H.B., Desdouits F., Girault J.A., Greengard P., Nairn A.C. Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins. Proc Natl Acad Sci USA 1997, 94:3536-3541.
24. Ammosova T., Obukhov Y., Kotelkin A., Breuer D., Beullens M., Gordeuk V.R., Bollen M., Nekhai S. Protein phosphatase-1 activates CDK9 by dephosphorylating Ser175. PLoS ONE 2011, 6:e18985.
25. Ammosova T., Platonov M., Yedavalli V.R., Obukhov Y., Gordeuk V.R., Jeang K.T., Kovalskyy D., Nekhai S. Small molecules targeted to a non-catalytic "RVxF" binding site of protein phosphatase-1 inhibit HIV-1. PLoS ONE 2012, 7:e39481.
26. Ammosova T., Jerebtsova M., Beullens M., Lesage B., Jackson A., Kashanchi F., Southerland W., Gordeuk V.R., Bollen M., Nekhai S. Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J Biol Chem 2005, 280:36364-36371.
27. Peti W., Nairn A.C., Page R. Structural basis for protein phosphatase 1 regulation and specificity. FEBS J 2013, 280:596-611.
28. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., Kaufman R.J., Ma D., Coen D.M., Ron D., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
29. Tsaytler P., Harding H.P., Ron D., Bertlotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011, 332:91-94.
30. Tappan E., Chamberlin A.R. Activation of protein phosphatase 1 by small molecule designed to bind to the enzyme's regulatory site. Chem Biol 2008, 15:167-174.
31. Chatterjee J., Beullens M., Sukackaite R., Qian J., Lesage B., Hart D.J., Bollen M., Köhn M. Development of a peptide that selectively activates protein phosphatase-1 in living cells. Angew Chem Int Ed 2012, 51:10054-10059.
32. Kelly A.E., Ghenoiu C., Xue J.Z., Zierhut C., Kimura H., Funabiki H. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010, 330:235-239.
33. Huertas D., Soler M., Moreto J., Villanueva A., Martinez A., Vidal A., Charlton M., Moffat D., Patel S., McDermott J., et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 2012, 31:1408-1418.
34. Kollareddy M., Zheleva D., Dzubak P., Brahmkshatriya P.S., Lepsik M., Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 2012, 30:2411-2432.
35. Copeland R.A., Olhava E.J., Porter Scott M. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol 2010, 14:505-510.
36. He R., Zeng L.F., He Y., Zhang S., Zhang Z.Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 2013, 280:731-750.
37. Yan Z., Hsieh-Wilson L., Feng J., Tomizawa K., Allen P.B., Fienberg A.A., Nairn A.C., Greengard P. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999, 2:13-17.
38. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 2012, 11:173-175.
39. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger P., Bös M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
40. Herzog F., Kahraman A., Boehringer D., Mak R., Bracher A., Walzthoeni T., Leitner A., Beck M., Hartl F.U., Ban N., et al. Structural probing of a protein phosphatase 2A network by chemical cross-linking and mass spectrometry. Science 2012, 337:1348-1352.
41. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
42. Siman P., Brik A. Chemical and semisynthesis of posttranslationally modified proteins. Org Biomol Chem 2012, 10:5684-5697.
43. Hayashi T., Hamachi I. Traceless affinity labeling of endogenous proteins for functional analysis in living cells. Acc Chem Res 2012, 45:1460-1469.
44. Riggsbee C.W., Deiters A. Recent advances in the photochemical control of protein function. Trends Biotechnol 2010, 28:468-475.
45. Krysiak J., Breinbauer R. Activity-based protein profiling for natural product target discovery. Top Curr Chem 2012, 324:43-84.
46. Shreder K.R., Liu Y., Nomanhboy T., Fuller S.R., Wong M.S., Gai W.Z., Wu J., Leventhal P.S., Lill J.R., Corral S. Design and synthesis of AX7574: a microcystin-derived, fluorescent probe for serine/threonine phosphatases. Bioconjug Chem 2004, 15:790-798.
47. Newman R.H., Zhang J. Visualization of phosphatase activity in living cells with a FRET-based calcineurin activity sensor. Mol Biosyst 2008, 4:496-501.
48. Terrak M., Kerff F., Langsetmo K., Tao T., Dominguez R. Structural basis of protein phosphatase 1 regulation. Nature 2004, 429:780-784.
49. Kelker M.S., Page R., Peti W. Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. J Mol Biol 2009, 385:11-21.